本帖最后由 maicon08 于 2023-4-28 15:12 编辑 ; u5 \* ^% b0 j% ^) w4 S0 @
% I" t2 x; {: O" X6 l5 d+ l% n一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。) S4 T6 e E+ c
5 o2 c0 F" p! `0 N9 S* h' W- l
https://www.163.com/dy/article/I3BTTPRD053438SI.html
% C6 E5 F# Y* m% `
" H' K. r( A! M1 g, \2 K% [$ |' s8 }
在研疗法-免疫治疗
* a" g! b! I( x( a- a. m* @# jDevelopmental Therapeutics—Immunotherapy
0 L9 s% [- m+ k' ^9 Y+ s* v8 V 7 T' k3 B. ^8 H s7 O
摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心
# l. d2 z" d5 c9 V$ |
在研疗法-分子靶向药物和肿瘤生物学) Q. t, q/ n: b2 M3 t+ |
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
, B- ] r0 H9 k. R% h, ~摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心
( S- t4 O y$ Z8 u
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院
5 p) x5 u. ~- n p; H
胃肠道肿瘤-结直肠癌和肛门癌8 I G: F* N$ w, ~. `" p
Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院 # N( z0 P9 K' F
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary 8 d. G& `) e1 g" @1 [
摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心
2 O& H) K2 [0 p9 M+ B, x7 `6 y8 _
妇科肿瘤 Gynecologic Cancer
7 ]: u5 _! O, n" c摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院
X% z1 T( I* y" B5 h3 X7 l
头颈肿瘤& a8 I4 F& X8 P+ E$ Z9 }7 i: f7 v
Head and Neck Cancer
# ?; |1 T0 Y; c( m摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心
& K$ A5 A- c+ ~* T5 T9 x, @( R6 ~
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心 * P$ f2 | c2 Z
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心 T2 j% K4 d9 Q# s1 d! k5 Q
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia - \. i( v4 P9 d) I
摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心 4 b- q( L) w) Z/ I
血液系统恶性肿瘤-浆细胞疾病0 V& C, ~5 x$ n5 a
Hematologic Malignancies—Plasma Cell Dyscrasia
1 S ]' F- r, L# g. @" g% Z2 C6 w摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院
( y3 {$ K+ | C: J/ P
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤
# \! j/ a% E4 G) y( X' m Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers 1 E8 w: [- c6 v3 `6 i8 m0 P+ K9 @% c* R/ o
摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院
; V6 ^& \) \/ b
肺癌-转移性非小细胞肺癌2 V; K' q5 P x: |3 W3 m
Lung Cancer—Non-Small Cell Metastatic
( f0 A' A+ E1 g5 T! C: p% z; V摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院
/ B& e; \+ l4 V4 r, B' b5 G$ G$ s8 B
' L4 N. X# g7 x" w- {4 f
摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院
9 h0 P" z6 z! v( H( `
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院 ; \* o( } k2 y! t
黑色素瘤/皮肤癌
! Z* ^8 V7 Q- I7 z+ u, j3 ?2 s Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院
! w& v1 V1 v. Y; p9 r
快速摘要报告4 m: p v9 Z) v
Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心 $ u7 U8 R. Z5 I( C6 K! k& f' A
临床科学研讨会& p3 O3 o3 I' L, S/ d8 s0 u# Q
Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院
. s2 d4 h. C- t; e% L1 C4 R6 Y+ @" J! ?* p) a; J
| 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
